^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    1d
    Comparison of Ovarian Tumor Homologous Recombination Deficiency (HRD) Status Generated from the Illumina TruSight Oncology 500 (TSO500) High-Throughput HRD Assay to the Myriad myChoice CDx Assay (AMP 2024)
    The FDA (US Food and Drug Administration) has approved olaparib as a front-line maintenance therapy in combination with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer with HRD+ status. We have demonstrated that the TSO500-HRD assay can accurately determine HRD status in ovarian tumors.
    BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Myriad myChoice® CDx • TruSight Oncology 500 Assay • TruSight Oncology 500 HRD Assay
    |
    Avastin (bevacizumab) • Lynparza (olaparib)
    1d
    Validation of a Homologous Recombination Deficiency (HRD) Assay for Use in Combination with Comprehensive Genomic Profiling (CGP) Testing (AMP 2024)
    The TruSight Oncology 500 comprehensive solid tumor next-generation sequencing panel with HRD assay demonstrated a high degree of sensitivity and specificity for deployment in a clinical setting.
    Combination therapy • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Myriad myChoice® CDx • TruSight Oncology 500 Assay • TruSight Oncology 500 HRD Assay
    2d
    SGNB7H4V-001: A Study of SGN-B7H4V in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=572, Recruiting, Seagen Inc. | N=430 --> 572 | Trial completion date: Jan 2027 --> Nov 2027 | Trial primary completion date: Jun 2025 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • PTEN mutation + HR positive
    |
    Keytruda (pembrolizumab) • felmetatug vedotin (PF-08046048)
    3d
    A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine (clinicaltrials.gov)
    P3, N=110, Not yet recruiting, AbbVie
    New P3 trial
    |
    Elahere (mirvetuximab soravtansine-gynx)
    3d
    TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • sapanisertib (CB-228) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    5d
    Ivonescimab (AK112) plus paclitaxel and carboplatin in frontline neoadjuvant therapy of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: a phase II trial (ChiCTR2400090496)
    P2, N=132, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial • Metastases
    |
    carboplatin • paclitaxel • Yidafan (ivonescimab)
    7d
    Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Washington | Trial primary completion date: Sep 2024 --> Dec 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    UW-Oncoplex™
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    8d
    STRO-002-GM2: A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=58, Recruiting, Sutro Biopharma, Inc. | Active, not recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • luveltamab tazevibulin (STRO-002)
    10d
    LYL797-101: A Study to Investigate LYL797 in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Lyell Immunopharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • CAR T-Cell Therapy
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    LYL797
    11d
    A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Pfizer | Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2025 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Zirabev (bevacizumab-bvzr)
    11d
    EFFORT: Adavosertib with or Without Olaparib in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=104, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)
    14d
    Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Pfizer | Phase classification: P1/2 --> P2
    Phase classification • Combination therapy
    |
    pegylated liposomal doxorubicin • maplirpacept (TTI-622)
    16d
    A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Oct 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Rubraca (rucaparib)
    18d
    AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=12, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Oct 2024
    Trial completion • Trial completion date
    |
    Imfinzi (durvalumab) • batiraxcept (AVB-500)
    22d
    NRG-GY007: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=147, Active, not recruiting, NRG Oncology | Trial completion date: Sep 2022 --> Aug 2025
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CRP (C-reactive protein)
    |
    carboplatin • paclitaxel • Jakafi (ruxolitinib)
    22d
    PRESERVE-004: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, OncoC4, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • gotistobart (BNT316)
    23d
    REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2/3, N=650, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)
    25d
    Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=22, Recruiting, University of Washington | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • carboplatin
    28d
    Tempus Priority Study: a Pan-tumor Observational Study (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Tempus AI | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    28d
    MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • bendamustine
    29d
    A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=170, Not yet recruiting, Bio-Thera Solutions | Initiation date: Sep 2024 --> Jan 2025
    Trial initiation date
    1m
    MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm. (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Royal Surrey County Hospital NHS Foundation Trust
    New trial • Surgery
    1m
    Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (clinicaltrials.gov)
    P2, N=78, Not yet recruiting, Mayo Clinic
    New P2 trial • Metastases
    1m
    NRG-GY021: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (clinicaltrials.gov)
    P2, N=61, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date • Tumor mutational burden
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Imjudo (tremelimumab)
    1m
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2024 --> Dec 2024
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    TP53 mutation • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    1m
    Seminal Abstract: Mirvetuximab Soravtansine (MIRV) in Recurrent Platinum-Sensitive Ovarian Cancer (PSOC) with High Folate Receptor-Alpha (FRα) Expression: Results from the PICCOLO Trial (IGCS 2024)
    97.5% had prior taxanes, 81% prior poly (ADP-ribose) polymerase inhibitors (PARPi) [74.7% of whom progressed while on PARPi], 64.6% prior bevacizumab, 98.8% had 2+ prior lines of therapy, and BRCA status was 27.8% positive, 72.2% negative. MIRV demonstrated notable efficacy in this heavily pretreated PSOC population, including among those who may have PARPi resistance. MIRV continues to demonstrate a differentiated safety profile consisting primarily of low-grade neurosensory, GI, and resolvable ocular AEs. These data position MIRV to become a novel treatment option for patients in ≥3L PSOC with FRα positive expression.
    PARP Biomarker • BRCA Biomarker
    |
    FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
    |
    FOLR1 expression
    |
    VENTANA FOLR1 RxDx Assay
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    1m
    SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Shattuck Labs, Inc. | Trial completion date: Apr 2025 --> Nov 2024
    Trial completion date
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    1m
    Study of Senaparib in Combination With Temozolomide (clinicaltrials.gov)
    P2, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial
    |
    temozolomide • senaparib (IMP4297)
    2ms
    NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=579, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Aug 2025
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    2ms
    Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Aug 2025
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    veliparib (ABT-888) • topotecan
    2ms
    A Case Study of a High-Grade Serous Carcinoma of the Fallopian Tube Transformed into Carcinosarcoma at the Site of Peritoneal Dissemination With Immunohistological Evidence of an Epithelial-Mesenchymal Transition. (PubMed, Int J Surg Pathol)
    The tumor of the omentum suggested that an EMT phenomenon was involved in the tumorigenesis. In this scenario, the primary HGSC of the fallopian tube with obvious invasion demonstrated that the conversion from carcinoma to sarcoma by EMT occurs only with peritoneal dissemination.
    Journal
    |
    TP53 (Tumor protein P53) • CDH1 (Cadherin 1) • TWIST1 (Twist Family BHLH Transcription Factor 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    |
    TP53 overexpression • ZEB1 expression
    2ms
    PIPACOVA: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Hospices Civils de Lyon | Phase classification: P2 --> P1 | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jun 2024 --> Jun 2026
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • carboplatin • paclitaxel • doxorubicin hydrochloride
    2ms
    Study of IMNN-001 (also Known As GEN-1) with NACT for Treatment of Ovarian Cancer (OVATION 2) (clinicaltrials.gov)
    P1/2, N=130, Active, not recruiting, Imunon | Trial completion date: Dec 2024 --> Nov 2025
    Trial completion date • Combination therapy • Metastases
    |
    carboplatin • paclitaxel • IMNN-001
    2ms
    DICE: Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (clinicaltrials.gov)
    P2, N=134, Completed, Imperial College London | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Nov 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    paclitaxel • sapanisertib (CB-228)
    2ms
    HOTT: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (clinicaltrials.gov)
    P3; Trial completion date: Aug 2038 --> Aug 2034 | Trial primary completion date: Aug 2033 --> Aug 2029
    Trial completion date • Trial primary completion date • Surgery
    |
    Myriad myChoice® CDx
    |
    cisplatin • Zejula (niraparib)
    2ms
    NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov)
    P1, N=221, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Sep 2024; Administratively Complete
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • Yervoy (ipilimumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • pemetrexed • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • daunorubicin • topotecan • leucovorin calcium • fluorouracil topical • Pemfexy (pemetrexed)
    2ms
    A real-world study evaluating the safety and efficacy of Mirvetuximab Soravtansine (MIRV) in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer with high folate receptor alpha expression (ChiCTR2400088269)
    P=N/A, N=50, Recruiting, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital Hainan Hospital; Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd.
    New trial • Real-world evidence • Real-world
    |
    FOLR1 ( Folate receptor alpha )
    |
    Elahere (mirvetuximab soravtansine-gynx)
    2ms
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Arsenal Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015
    2ms
    Surgery for Ovarian Cancer After PARPi Therapy in Precision (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, Shanghai Gynecologic Oncology Group
    New P1/2 trial • Surgery
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab)
    2ms
    NCI-2018-01240: Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab)
    2ms
    HIPEC: Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy (clinicaltrials.gov)
    P2, N=10, Recruiting, Wake Forest University Health Sciences | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Aug 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • HEOR
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    carboplatin
    2ms
    NCI-2018-01758: Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=4, Terminated, Roswell Park Cancer Institute | Trial completion date: Jan 2027 --> Jun 2024 | Active, not recruiting --> Terminated; Lack of funding
    Trial completion date • Trial termination
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    melphalan • Proleukin (aldesleukin)